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1. Summary 
P-450 metabolites, including the epoxyeicosatrienoic acids, are likely candidates for 
endothelial derived hyperpolarising factor (EDHF). In the present study, we confirm 
that the stable analogue 11-nonyloxyundec-8(Z)-enoic acid is a vasodilator of murine 
vessels. However, we also show that the ‘epoxyeicosatrienoic acid receptor’ antagonist 
14, 15 EEZE similarly dilates murine vessels contracted with U46619, prostaglandin 
F2α or methoxamine, but not with endothelin-1 or potassium. We suggest that 14,15 
EEZE is a partial agonist for the epoxyeicosatrienoic acids/EDHF receptor. These 
results illustrate an important pharmacological property of this antagonists, which is 
being increasingly used to study the nature of EDHF. 
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2. Introduction 
The endothelium plays a key role in the control of vasomotor tone via the 
release of diffusible factors such as prostanoids, nitric oxide, and endothelial 
derived hyperpolarising factor (EDHF). The identity of EDHF is controversial, 
although there has been considerable support for a role of cytochrome P450 (CYP) 
metabolites (Archer et al., 2003; Campbell et al., 1996; Fisslthaler et al., 1999). 
However, the specific pharmacological tools required for investigating this theory 
have only recently been made available (Falck et al., 2003; Gauthier et al., 2002).  
 Epoxyeicosatrienoic acids are CYP metabolites, which induce vasodilatation  
by activating smooth muscle large conductance Ca2+ sensitive K+ (BKCa) (Archer et 
al, 2003). The epoxyeicosatrienoic acids are currently thought to be important 
mediators in EDHF responses. Specifically, acetylcholine induced vasodilatation, in 
human and bovine tissue, is inhibited by P450 inhibitors and by the 
epoxyeicosatrienoic acid analogue 14, 15-epoxyeicosa-5 (Z) enoic acid (14, 15 
EEZE) (Archer et al, 2003; Gauthier et al, 2002). 14, 15 EEZE may therefore 
represent the first EDHF antagonist and consequently is a very useful 
pharmacological tool in the study of vascular biology. However, a full 
pharmacological analysis of 14, 15, EEZE has not been made. In the present study 
we present data which shows that 14, 15 EEZE is a vasodilator in its own right. In 
fact, 14, 15 EEZE was more potent a vasodilator than the ‘agonist’ 11-
nonyloxyundec-8(Z)-enoic acid (Falck et al., 2003).  
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3. Methods  
Male Black 6 C57 mice (28.2 ± 1.24g) were killed by lethal exposure to CO2. 
The mice were maintained and killed in accordance with the European Community 
guidelines for the use of experimental animals. The mesenteric bed was removed using 
ligatures, and placed into physiological salt solution (PSS; composition in mM) NaCl 
119, KCl 4.7, CaCl2 2.5, MgSO4 1.17, NaHCO3 25, KH2PO4 1.18, EDTA 0.027, and 
Glucose 5.5. Segments of first order mesenteric artery were removed and mounted in a 
four channel Mulvany-Halpern myograph under normalised tension (Mulvany and 
Halpern, 1977). In this study, the second order arteries had a mean internal diameter of 
226µm. The vessels were equilibrated to 37oC and the solution gassed with 95% O2 and 
5% CO2 for 30 minutes. The arterial segments were challenged twice with high 
potassium solution (KPSS; composition in mM: KCl 123.7, CaCl2 2.5, MgSO4 1.17, 
NaHCO3 25, KH2PO4 1.18, EDTA 0.027, and Glucose 5.5), after washing either 9, 11- 
Dideoxy-11α, 11α-epoxymethanoprostaglandin F2α (U46619), prostaglandin F2α, 
methoxamine or endothelin 1 was added in a cumulative fashion in order to determine 
the EC80 concentration of each drug to induce contraction. The presence of an intact 
endothelium was confirmed by the ability of 10-5M acetylcholine to induce >70% 
relaxation of U46619 (EC80) precontracted vessels. Occasionally vessels failed this test 
and were disregarded.  
 
3.1 Effects of the agonists 11-nonyloxyundec-8(Z)-enoic acid or the antagonists 14, 15 
EEZE on vasodilator effects in pre-contracted vessels 
Vessels were precontracted with the EC80 concentration of U46619 followed by the 
cumulative addition of either 11-nonyloxyundec-8(Z)-enoic acid or 14, 15 EEZE. In 
some experiments, vessels were pre-contracted with 10-5M methoxamine. The 
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inhibitory effects of 14, 15 EEZE were investigated by incubation in the presence of 10-
5M 14, 15 EEZE for 30 minutes prior to the contraction with U46619 (10-8M – 10-6M) 
or methoxamine (3x10-8M – 10-4M). In experiments where 10-5M 14, 15 EEZE was 
used, 11-nonyloxyundec-8(Z)-enoic acid (3x10-9M – 3x10-5M) was added in a 
cumulative fashion after contraction with U46619.  
 
3.2 Materials 
 All drugs were purchased from Sigma Chemical Co. Gillingham, Dorset, UK, 
except for 11-nonyloxyundec-8(Z)-enoic acid and 14, 15-EEZE, which were a gift 
generously provided by J. R. Falck (Department of Pharmacology and Toxicology, 
University of Texas South-western Medical school, Dallas). 
Acetylcholine and methoxamine solutions were freshly prepared each day in 
aqueous solutions. 14, 15-EEZE, 11-nonyloxyundec-8(Z)-enoic acid, U46619 or PGF2α 
were prepared in high concentration ‘stock’ solutions dissolved in ethanol and were 
stored at -80oC until used. Endothelin-1, dissolved in 0.1% acetic acid was also stored 
at -80oC in aliquots until used. Where appropriate vehicle (ethanol) was added to 
control arteries and responses defined as ‘time control’. 
 
3.3 Data and statistical analysis 
Contractile responses were represented as active effective pressure (AEP; kPa; 
mN/mm2) as calculated by the following equations:  
ΔT = ΔF/2 x segment length 
AEP = ΔT/(vessel radius) 
Where ΔT represents active wall tension and ΔF represents active force response 
measured in mN. 
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Relaxant responses were calculated as a percentage of induced tone. Data are 
given as the mean ± S.E.M. for experiments (1 animal per experiment).  
 
4. Results 
4.1 Effects of 14, 15 EEZE on vasodilator responses 
 U46619 induced concentration dependent vasoconstriction of vessels. Pre-
treatment of vessels with 14, 15 EEZE resulted in concentration dependent inhibition of 
U46619 induced contractions (figure 1a). Similarly, methoxamine induced 
concentration dependent vasoconstriction of vessels which were also inhibited by 14, 
15 EEZE (figure 1b). 14, 15 EEZE appeared more potent an inhibitor of U46619 than 
methoxamine induced vasoconstriction.  
14, 15 EEZE was also able to induce direct and immediate vasodilator responses 
in vessels contracted with EC80 concentrations of U46619 (3x 10-8M), PGF2α (10-5M), 
or methoxamine (10-5M). By contrast, 14, 15 EEZE did not dilate vessels contracted 
with an EC80 concentration of endothelin-1 (10-8M) or with depolarising concentrations 
of potassium (1.24x10-2M), (figure 2a). 
 
4.2 Effect of 11-nonyloxyundec-8(Z)-enoic acid on vasodilator responses 
11-nonyloxyundec-8(Z)-enoic acid induced vasodilator responses in U46619 
contracted vessels with an approximate EC50 of approximately 10-5M (figure 2b). The 
dilator effects 11-nonyloxyundec-8(Z)-enoic acid were antagonised by 10-5M 14, 15 
EEZE (Figure 2b). 
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5. Discussion 
11-nonyloxyundec-8(Z)-enoic acid and 14, 15 EEZE are pharmacological tools 
used to investigate EDHF candidates. In the present study we show that 11-
nonyloxyundec-8(Z)-enoic acid is an effective vasodilator of murine mesenteric 
vessels. We also show that 14, 15 EEZE is an effective antagonist of these responses. 
However, we also show that 14, 15 EEZE is a vasodilator with a similar potency to 11-
nonyloxyundec-8(Z)-enoic acid .  
Vasodilator epoxyeicosatrienoic acids are metabolic products of arachidonic 
acid breakdown by cytochrome P-450 epoxygenases in the endothelium. However, 
cytochrome P-450 ω-hydroxylase metabolises arachidonic acid in the smooth muscle 
cells to form 20-hydroxyeicosatetraenoic acid (20-HETE), which may induce 
vasoconstriction. Thus, the ratio of arachidonic acid metabolites present in the vessel 
wall dictates the level of tone of the smooth muscle cells, and any antagonist used to 
study these enzymes needs to be highly specific. Consequently, Gauthier and co-
workers (2002) designed and generated a range of analogues, of which 14, 15 EEZE 
was found to have important effects. 14, 15 EEZE was found to be a highly specific 
epoxyeicosatrienoic acid antagonist, with no effect on the action or synthesis of 20-
HETE (Gauthier et al., 2000). 
It has been proposed that the endothelium synthesises epoxyeicosatrienoic acids 
which are released upon stimulation by agonist such as acetylcholine. The released 
epoxyeicosatrienoic acids open large KCa channels in smooth muscle cells, and thus 
induce hyperpolarisation and relaxation of the artery (Campbell et al, 1996). However, 
the vascular type may be sensitive to the type of epoxyeicosatrienoic acid released, 
since rat renal arteries relax in the presence of 11-nonyloxyundec-8(Z)-enoic acid but 
14, 15 epoxyeicosatrienoic acid had little effect (Zou et al., 1996). 
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The dilator actions of the stable epoxyeicosatrienoic acid analogue 11-
nonyloxyundec-8(Z)-enoic acid were abolished by 14, 15 EEZE. This observation is 
consistent with the notion that 14, 15 EEZE is an antagonist of 11-nonyloxyundec-8(Z)-
enoic acid and is in line with findings of Archer et al (2003) and Gauthier et al (2002). 
However, in the current study we have characterised a vasodilator property of 14, 15 
EEZE. Specifically we show that 14, 15 EEZE inhibits contractions induced by U46619 
or methoxamine. Furthermore, we show that 14, 15 EEZE induces vasodilatation of 
vessels contracted with U46619 or PGF2α. Similar observations have previously been 
reported using bovine coronary artery as a bioassay (Gauthier et al 2002), although in 
this tissue dilator effects were very weak. In the current study we also demonstrate that 
14, 15 EEZE is an effective, but less potent and less efficacious dilator of vessels 
contracted with methoxamine. By contrast, 14, 15 EEZE did not dilate vessels 
contracted with either endothelin-1 or high potassium; both of which will depolarise 
vessels as they contract (Van Renterghem et al., 1989). Under these conditions, 
hyperpolarising vasodilators are inactive. This data suggests that the vasodilator 
properties of 14 15 EEZE are mediated, like those of 11-nonyloxyundec-8(Z)-enoic 
acid, via smooth muscle cell hyperpolarisation. 
This data supports the use of 14, 15 EEZE as an epoxyeicosatrienoic acids receptor 
antagonist. However, our data also illustrates other important pharmacological 
properties of this drug. Specifically, our data suggest that 14, 15 EEZE is an agonist or 
partial agonist for the putative epoxyeicosatrienoic acids receptor. 
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7. Figure legends  
 
 
Figure 1. Effects of pre-incubation with 14, 15 EEZE on contraction with either 
U46619 (a) or methoxamine (b). Data are given as active effective pressure (AEP; kPa), 
all values are means ± S.E.M. of 3 to 5 experiments. 
 
Figure 2. Dilator properties of 14, 15 EEZE on vessels contracted with potassium 
(1.24x10-2M; KPSS), prostaglandin F2α (PGF2α; 10-5M), U46619 (3x 10-8M), 
endothelin 1 (10-8M) or methoxamine (10-5M),(a). Antagonistic effects of 14, 15 EEZE 
(10-5M) on 11-nonyloxyundec-8(Z)-enoic acid induced vasodilation in vessels 
contracted with U46619 (10-7M), (b). Data are given as percentage of U46619 induced 
tone; all values are means ± S.E.M. of 3 to 5 experiments. 
